Opdivo (nivolumab) 100 mg/10 mL concentrate for solution for infusion — original (Bristol-Myers Squibb, USA) Opdivo (nivolumab) is a drug for the treatment of patients with inoperable or metastatic melanoma. Targeted cancer therapy. Drug delivery from Europe. +380996042415

Indications

Opdivo (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma, particularly those with BRAF mutations, who have failed BRAF inhibitors; and for the treatment of patients with metastatic squamous cell lung cancer. Treatment with nivolumab is administered under the supervision of a physician, who determines the dosage and frequency of administration based on current standard treatment protocols. If significant side effects occur, the physician may discontinue the drug or adjust the dosage.

Analogs: There are no known analogs.